KRSA: KRSA-028 aims to pair brain-shuttled plaque clearance with monthly subcutaneous dosing
阅读少于1分钟
KRSA-028 combines a brain shuttle, modified effector function and subcutaneous dosing, with the goal of improving convenience and safety while retaining plaque clearance. CTA is planned by end-2026, with SAD data expected mid-2027.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
© AI-generated summary is provided by Quartr